Barclays PLC Increases Stock Holdings in Sight Sciences, Inc. (NASDAQ:SGHT)

Barclays PLC increased its holdings in shares of Sight Sciences, Inc. (NASDAQ:SGHT) by 317.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,300 shares of the company’s stock after buying an additional 38,248 shares during the quarter. Barclays PLC’s holdings in Sight Sciences were worth $317,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in SGHT. State Street Corp grew its holdings in Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after buying an additional 95,843 shares during the period. Long Focus Capital Management LLC grew its holdings in Sight Sciences by 86.9% in the second quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock valued at $3,739,000 after purchasing an additional 260,594 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in Sight Sciences by 46.3% during the third quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock worth $1,310,000 after purchasing an additional 65,767 shares during the period. B. Riley Wealth Advisors Inc. acquired a new position in shares of Sight Sciences in the 2nd quarter valued at $1,234,000. Finally, Millrace Asset Group Inc. acquired a new position in shares of Sight Sciences in the 3rd quarter valued at $874,000. 55.51% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Sight Sciences news, insider Matthew Link sold 21,831 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $5.61, for a total transaction of $122,471.91. Following the completion of the sale, the insider now owns 663,550 shares in the company, valued at $3,722,515.50. This trade represents a 3.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have acquired 15,000 shares of company stock worth $58,232 and have sold 63,052 shares worth $367,522. Insiders own 28.90% of the company’s stock.

Sight Sciences Trading Down 2.5 %

SGHT opened at $3.49 on Friday. The firm’s 50 day moving average is $4.01 and its 200-day moving average is $5.62. Sight Sciences, Inc. has a 52-week low of $3.30 and a 52-week high of $8.45. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $177.13 million, a P/E ratio of -3.42 and a beta of 2.58.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The firm had revenue of $20.16 million for the quarter, compared to the consensus estimate of $20.41 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. Analysts expect that Sight Sciences, Inc. will post -1.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SGHT. Piper Sandler reaffirmed a “neutral” rating and issued a $5.50 target price (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a report on Friday, November 8th. Morgan Stanley dropped their target price on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday, November 11th. Citigroup reduced their price target on shares of Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Finally, Lake Street Capital lowered shares of Sight Sciences from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $10.00 to $5.00 in a research report on Monday, November 4th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.12.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.